A Phase I/IIa, Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of SNK01 in Participants With Moderate Alzheimer's Disease is a PHASE1 clinical asset sponsored by NKGen Biotech, Inc. in Moderate Alzheimer Disease. SEO and diligence focus: SNK01, Placebo, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.